
    
      The study aims to find whether patients with advanced HCC can get more benefits from RFA
      +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the
      result of PFS. 120 patients were enrolled into two groups respectively, the experimental
      group and reference group.
    
  